Business Context and Reporting Period
ImmuCell Corporation (ICCC), a Delaware corporation headquartered in Portland, Maine, filed this Form 8-K on July 9, 2026. The report addresses preliminary, unaudited sales results for the second quarter (Q2) ended June 30, 2026.
Key Financial Metrics
- Product Sales Growth: Reported an 11.5% increase in product sales for Q2 2026 compared to Q2 2025.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for total revenue, net profit, operating cash flow, or margins.
- Debt and Liquidity: The filing text does not provide specific values for debt levels or liquidity metrics.
Material Changes
The primary material change disclosed is the 11.5% year-over-year increase in product sales for the quarter ended June 30, 2026, relative to the same period in 2025.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) containing the full announcement but does not include specific forward-looking guidance, management commentary, risk factors, or contingencies within the body of this 8-K text. The information regarding sales results is explicitly noted as preliminary and unaudited.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for detailed sales figures and any additional commentary not included in the 8-K summary.
- Verify the final audited financial statements for Q2 2026 to confirm the preliminary 11.5% sales growth figure.
- Check subsequent filings for full revenue, profit, and cash flow data which are absent from this current report.